NCT07298447Phase 3Recruiting

Donidalorsen Treatment in Children With Hereditary Angioedema

Study sponsor: Ionis Pharmaceuticals, Inc. · IONS

Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.

Open ClinicalTrials.gov record CSV export · Pro

Primary completion2029-06Estimated

Enrollment · participants20Estimated

Source updated2026-09-02Last update listed in the registry record

Version history

Changes to this trial

Last 12 months

Pro unlocks the full available history and CSV export. View Pro features

Posted 2026-03-17 · 1 field changed

Recruitment status

Recorded edit

− Previous value

Not yet recruiting

+ Updated value

Recruiting

Check registry source

Study details

Conditions studied

Hereditary Angioedema (HAE)

Treatments or interventions studied

DonidalorsenDrugAlso known as ISIS 721744, IONIS-PKK-LRx

Primary outcomes · main study measures

Read the study measures

measure: Number of Participants with Treatment Emergent Adverse Events (TEAEs); timeFrame: over the period of approximately 17 months; measure: Maximum Plasma Concentration (Cmax) of Donidalorsen; timeFrame: over the period of approximately 17 months; measure: Maximum Time to Reach Cmax (Tmax) of Donidalorsen; timeFrame: over the period of approximately 17 months; measure: Trough Plasma Concentration (Ctrough) of Donidalorsen; timeFrame: over the period of approximately 17 months

History coverage

Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.

How to read this history